Monitor for upcoming KROS pipeline catalysts (clinical trial readouts) and any 8-K filings that might explain the coordinated officer selling. The C-suite cluster sell at identical prices on the same day is unusual for a pre-revenue biotech — watch for a potential equity offering or restructuring announcement. If the selling was tax-related, it is neutral; if it precedes negative clinical data, it is bearish. The director buy provides a modest counter-signal but is too small to override the officer cluster.
Price Chart
Executive Summary
Keros Therapeutics insiders executed a mixed cluster: one director bought $10K worth of shares, while three C-suite officers and one director sold a combined $101K on the same day. The selling is concentrated among senior executives (CSO, CLO, VP Finance) at identical prices, suggesting coordinated liquidity or tax-related selling rather than a bearish signal, but the asymmetry between a small director buy and larger officer sells warrants attention. At $220M market cap, the $111K total is ~0.05% of market cap — trivial in magnitude, but the C-suite cluster sell pattern is notable given the company's pre-revenue biotech status and upcoming pipeline catalysts.
Key Financial Metrics
Key Facts
- Director Jean Jacques Bienaime bought 1,000 shares at $10.27 for $10,270 on 2026-08-17.
- CSO Lorena Lerner sold 3,568 shares at $10.29 for $36,715 on 2026-08-18.
- CLO Esther Cho sold 4,485 shares at $10.29 for $46,151 on 2026-08-18.
- VP Finance Annita Tanini sold 1,224 shares at $10.29 for $12,595 on 2026-08-18.
- Director Charles Newton sold 551 shares at $10.30 for $5,675 on 2026-08-18.
- Total cluster value of $111K represents ~0.05% of KROS's $220M market cap.
- Three C-suite officers sold on the same day at identical prices, suggesting a coordinated event (e.g., tax withholding, 10b5-1 plan, or blackout window opening).
- The single director buy is small and does not offset the officer sell cluster.
Financial Impact
Total insider trading of $111K, with $101K in sales and $10K in purchases, representing ~0.05% of market cap.
Risk Factors
- Coordinated C-suite selling may indicate upcoming negative clinical trial results or financing dilution.
- Pre-revenue biotech with $220M market cap is highly sensitive to pipeline data — insider selling ahead of catalysts is a red flag.
- The director buy is small ($10K) and may be a routine diversification or signaling gesture, not a conviction signal.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-KROS-1787292502397 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 8, 2026 23d ago | 8-K | $11.31 $11.04 | ▼ −2.39% | ▼ −2.05% | $11.17 (−1.24%) |
Aug 20, 2026 6w ago | Insider Cluster | $10.95 $11.23 | ▲ +2.56% | ▲ +1.44% | $11.17 (+2.01%) |
Aug 3, 2026 8w ago | 8-K | $10.25 $10.64 | ▲ +3.80% | ▲ +3.90% | $11.17 (+8.98%) |
Aug 3, 2026 8w ago | Press Release | $10.25 $10.64 | ▲ +3.80% | ▲ +3.90% | $11.17 (+8.98%) |
Jul 30, 2026 9w ago | 8-K | $10.07 $11.15 | ▲ +10.72% | ▲ +7.21% | $11.17 (+10.92%) |
Jul 22, 2026 10w ago | 8-K | $10.14 $10.22 | ▲ +0.79% | ▲ +0.31% | $11.17 (+10.16%) |
Jun 17, 2026 15w ago | Insider Cluster | $10.65 $10.41 | ▼ −2.25% | ▼ −0.59% | $11.17 (+4.88%) |
Jun 8, 2026 16w ago | Insider Cluster | $10.07 $10.24 | ▲ +1.69% | ▼ −0.72% | $11.17 (+10.92%) |
May 14, 2026 20w ago | 8-K | $10.99 $11.22 | ▼ −2.09% | ▼ −2.81% | $11.17 (−1.64%) |
May 14, 2026 20w ago | Press Release | $10.99 $11.22 | ▼ −2.09% | ▼ −2.81% | $11.17 (−1.64%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access